Regents of the University of California

RAPT Therapeutics, Inc., established in 2015 and headquartered in South San Francisco, California, is a clinical-stage biopharmaceutical company specializing in immunology-based therapies. The company focuses on developing oral small molecule treatments for patients with unmet needs in oncology and inflammatory diseases. Its lead drug candidates are FLX475, an oral C-C motif chemokine receptor 4 antagonist in Phase 2 clinical trials for various cancer types, and RPT193, which selectively inhibits type 2 T helper cell migration into inflamed tissues. Additionally, RAPT is exploring other targets like general control nonderepressible 2 and hematopoietic progenitor kinase 1 in the discovery phase.

Peloton Therapeutics, Inc. is a clinical stage biopharmaceutical company based in Dallas, Texas, dedicated to developing innovative medicines for cancer and other serious conditions. Its lead candidate, PT2977, is an oral HIF-2a inhibitor currently undergoing Phase 2 clinical trials for advanced or metastatic clear cell renal cell carcinoma. Additionally, PT2977 is being tested in various combinations and settings, including von Hippel-Lindau disease associated renal cell carcinoma and glioblastoma multiforme. The company is also working on PT2567, another HIF-2a inhibitor in preclinical development targeting non-oncology conditions such as pulmonary arterial hypertension. Founded in 2010 by Steven L. McKnight and supported by the Cancer Prevention Research Institute of Texas and experienced investors, Peloton aims to leverage its scientific collaborations and robust pipeline to establish itself as a leading biotech firm in cancer drug discovery and development.

Peloton Therapeutics, Inc. is a clinical stage biopharmaceutical company based in Dallas, Texas, dedicated to developing innovative medicines for cancer and other serious conditions. Its lead candidate, PT2977, is an oral HIF-2a inhibitor currently undergoing Phase 2 clinical trials for advanced or metastatic clear cell renal cell carcinoma. Additionally, PT2977 is being tested in various combinations and settings, including von Hippel-Lindau disease associated renal cell carcinoma and glioblastoma multiforme. The company is also working on PT2567, another HIF-2a inhibitor in preclinical development targeting non-oncology conditions such as pulmonary arterial hypertension. Founded in 2010 by Steven L. McKnight and supported by the Cancer Prevention Research Institute of Texas and experienced investors, Peloton aims to leverage its scientific collaborations and robust pipeline to establish itself as a leading biotech firm in cancer drug discovery and development.

RAPT Therapeutics, Inc., established in 2015 and headquartered in South San Francisco, California, is a clinical-stage biopharmaceutical company specializing in immunology-based therapies. The company focuses on developing oral small molecule treatments for patients with unmet needs in oncology and inflammatory diseases. Its lead drug candidates are FLX475, an oral C-C motif chemokine receptor 4 antagonist in Phase 2 clinical trials for various cancer types, and RPT193, which selectively inhibits type 2 T helper cell migration into inflamed tissues. Additionally, RAPT is exploring other targets like general control nonderepressible 2 and hematopoietic progenitor kinase 1 in the discovery phase.

Sprinter Health is a mobile health company that specializes in providing on-demand healthcare services directly to patients' homes. By sending full-time nurses and phlebotomists, known as "Sprinters," the company aims to improve access to preventive care and enhance the overall patient experience. Sprinter Health employs a cost-effective, hybrid care model that facilitates connections between patients and necessary healthcare services, ultimately striving to improve health outcomes and patient satisfaction. This approach allows patients to receive quality medical care in the comfort of their own homes, ensuring convenience and accessibility without compromising on care quality.